IE
KROS icon

Israel Englander’s Keros Therapeutics KROS Stock Holding History

Israel Englander’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.98M Buy
184,822
+77,964
+73% +$868K ﹤0.01% 3830
2026
Q1 		$1.18M Sell
106,858
-113,351
-51% -$1.75M ﹤0.01% 4271
2025
Q4 		$4.48M Buy
220,209
+166,863
+313% +$2.93M ﹤0.01% 3136
2025
Q3 		$844K Buy
53,346
+39,641
+289% +$586K ﹤0.01% 4747
2025
Q2 		$183K Sell
13,705
-219,498
-94% -$2.96M ﹤0.01% 5390
2025
Q1 		$2.38M Sell
233,203
-644,956
-73% -$7.49M ﹤0.01% 3617
2024
Q4 		$13.9M Buy
878,159
+305,169
+53% +$15.9M 0.01% 1854
2024
Q3 		$33.3M Buy
572,990
+180,034
+46% +$8.89M 0.02% 1120
2024
Q2 		$18M Buy
392,956
+55,293
+16% +$2.97M 0.01% 1598
2024
Q1 		$22.4M Sell
337,663
-184,465
-35% -$10.9M 0.01% 1472
2023
Q4 		$20.8M Buy
522,128
+318,071
+156% +$9.97M 0.01% 1512
2023
Q3 		$6.51M Buy
204,057
+164,161
+411% +$6.13M ﹤0.01% 2448
2023
Q2 		$1.6M Buy
39,896
+15,523
+64% +$680K ﹤0.01% 3669
2023
Q1 		$1.04M Sell
24,373
-156,904
-87% -$7.92M ﹤0.01% 4058
2022
Q4 		$8.71M Buy
+181,277
New +$8.47M ﹤0.01% 2286
2022
Q2 		– Sell
-65,688
Closed -$3.57M – 7244
2022
Q1 		$3.57M Buy
65,688
+12,944
+25% +$664K ﹤0.01% 3308
2021
Q4 		$3.09M Sell
52,744
-129,132
-71% -$6.44M ﹤0.01% 3353
2021
Q3 		$7.2M Buy
181,876
+64,961
+56% +$2.31M ﹤0.01% 2448
2021
Q2 		$4.96M Sell
116,915
-13,350
-10% -$723K ﹤0.01% 2764
2021
Q1 		$8.02M Buy
130,265
+42,309
+48% +$2.68M 0.01% 2036
2020
Q4 		$6.2M Buy
87,956
+79,217
+906% +$4.99M ﹤0.01% 2233
2020
Q3 		$337 Buy
+8,739
New +$347K ﹤0.01% 3778

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Israel Englander's KROS Position: Q2 2026 in Review

Israel Englander increased its Keros Therapeutics (KROS) stake by 73% in Q2 2026, buying an estimated $868K and bringing the position to 184,822 shares worth $1.98M. The position accounts for ﹤0.01% of the portfolio, ranked #3830.

Israel Englander first reported a position in KROS in Q3 2020 and has held it in 22 quarters since. The position peaked at $33.3M in Q3 2024. 131 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Israel Englander held 184,822 shares of Keros Therapeutics worth $1.98M as of Q2 2026.
  • Israel Englander bought 77,964 Keros Therapeutics shares in Q2 2026, an estimated $868K.
  • Keros Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3830 holding.
  • Israel Englander first reported a position in Keros Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • Israel Englander's Keros Therapeutics position peaked at $33.3M in Q3 2024.
  • 131 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.